We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Analysis of a new antibiotic with 91% efficacy in carbapenem-resistant pneumonia. Why the market dooms it to failure and who will profit. Read the details.
